Home > Insider Trading > Filing (0001062993-24-020566)

Filing Details

Accession Number:: 0001062993-24-020566
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-12-12 20:08:18
Reporting Period:: 2024-12-10

Accepted Time:: 2024-12-12 20:08:18
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1661181	Organogenesis Holdings Inc.	ORGO	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1757373	S. Gary Gillheeney	C/O Organogenesis Holdings Inc. 85 Dan Road Canton MA 02021	President And Ceo	Yes	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Class A Common Stock	Disposition	2024-12-10	58,525	$3.64	3,301,201	No	4	S	Direct
Class A Common Stock	Disposition	2024-12-11	157,448	$3.64	3,143,753	No	4	S	Direct
Class A Common Stock	Disposition	2024-12-12	43,359	$3.55	3,100,394	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The reported disposition represents the sale of shares to cover the withholding tax that was previously paid to the issuer arising from the exercise of the expiring stock option reported on the Form 4 filed by the reporting person on December 9, 2024.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.4531 to $3.74, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.51 to $3.72, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.495 to $3.65, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.